Fezolinetant is a proprietary, oral, small-molecule antagonist of the NK3 receptor, discovered and developed by Ogeda for the treatment of Women’s Health Disorders

Fezolinetant is superior to the existing, marketed GnRH ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis. In addition, its selective action on gonadotropins uniquely positions fezolinetant for the treatment of PCOS. Furthermore, its mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women.